{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:00:12Z","timestamp":1780581612535,"version":"3.54.1"},"reference-count":75,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>One of the main groups of lipids is phospholipids, which are mainly involved in forming cell membranes. Neoplastic processes such as cell replication have increased lipid synthesis, making tumor cells dependent on this synthesis to maintain their requirements. Antiphospholipid antibodies attack phospholipids in the cell membranes. Three main types of antiphospholipid antibodies are recognized: anti-\u03b22 glycoprotein I (anti-\u03b22GP-I), anticardiolipin (aCL), and lupus anticoagulant (LA). These types of antibodies have been proven to be present in hematological neoplasms, particularly in LH and NHL. This review on antiphospholipid antibodies in hematological neoplasms describes their clinical relationship as future implications at the prognostic level for survival and even treatment.<\/jats:p>","DOI":"10.3390\/ijms23084151","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T05:13:08Z","timestamp":1649481188000},"page":"4151","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antiphospholipid Antibodies and Lipids in Hematological Malignancies"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-1581","authenticated-orcid":false,"given":"Sonia Guadalupe","family":"Barreno-Rocha","sequence":"first","affiliation":[{"name":"Unidad de Investigaci\u00f3n Epidemiol\u00f3gica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico"},{"name":"Programa de Doctorado en Farmacolog\u00eda, Departamento de Fisiolog\u00eda, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-2994","authenticated-orcid":false,"given":"Sandra","family":"Guzm\u00e1n-Silahua","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Epidemiol\u00f3gica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico"},{"name":"Programa de Doctorado en Farmacolog\u00eda, Departamento de Fisiolog\u00eda, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina\u00ed-del-Carmen","family":"Rodr\u00edguez-D\u00e1vila","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Epidemiol\u00f3gica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe Estela","family":"Gavilanez-Ch\u00e1vez","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Epidemiol\u00f3gica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico"},{"name":"Programa de Doctorado en Farmacolog\u00eda, Departamento de Fisiolog\u00eda, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto Germ\u00e1n","family":"Cardona-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Programa de Doctorado en Farmacolog\u00eda, Departamento de Fisiolog\u00eda, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Riebeling-Navarro","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n en Epidemiologia Cl\u00ednica, UMAE HP CMN-SXXI, Ciudad de M\u00e9xico 06720, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjam\u00edn","family":"Rubio-Jurado","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Epidemiol\u00f3gica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico"},{"name":"Departamento Cl\u00ednico de Hematolog\u00eda, Divisi\u00f3n Onco-Hematologia, UMAE, Hospital de Especialidades, Centro M\u00e9dico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3061-521X","authenticated-orcid":false,"given":"Arnulfo Hern\u00e1n","family":"Nava-Zavala","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Epidemiol\u00f3gica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico"},{"name":"Programa Internacional de Medicina, Universidad Aut\u00f3noma de Guadalajara, Guadalajara 44670, Mexico"},{"name":"Departamento de Inmunolog\u00eda y Reumatolog\u00eda del Hospital General de Occidente, Secretar\u00eda de Salud Jalisco, Guadalajara 45070, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbalip.2011.06.009","article-title":"Lipid classification, structures and tools","volume":"1811","author":"Fahy","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000365423","article-title":"Introduction to fatty acids and lipids","volume":"112","author":"Burdge","year":"2015","journal-title":"World Rev. Nutr. Diet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrm.2017.138","article-title":"Understanding the diversity of membrane lipid composition","volume":"19","author":"Harayama","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/femsre\/fuv008","article-title":"Bacterial membrane lipids: Diversity in structures and pathways","volume":"40","author":"Sohlenkamp","year":"2016","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ridgway, N.D., and McLeod, R.S. (2016). Chapter 1\u2014Functional Roles of Lipids in Membranes. Biochemistry of Lipids, Lipoproteins and Membranes, Elsevier. [6th ed.].","DOI":"10.1016\/B978-0-444-63438-2.00001-8"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1039\/C8AN01046C","article-title":"Lipid metabolism in inflammation-related diseases","volume":"143","author":"Zhang","year":"2018","journal-title":"Analyst"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1021\/cr200363s","article-title":"Introduction to Lipid Biochemistry, Metabolism, and Signaling","volume":"111","author":"Brown","year":"2011","journal-title":"Chem. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Afonso, M.S., Machado, R.M., Lavrador, M.S., Quintao, E.C.R., Moore, K.J., and Lottenberg, A.M. (2018). Molecular Pathways Underlying Cholesterol Homeostasis. Nutrients, 10.","DOI":"10.3390\/nu10060760"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.bbalip.2016.12.006","article-title":"Archaeal phospholipids: Structural properties and biosynthesis","volume":"1862","author":"Caforio","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.bbamcr.2013.05.018","article-title":"The role of phospholipids in the biological activity and structure of the endoplasmic reticulum","volume":"1833","author":"Lagace","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10863-015-9601-4","article-title":"Mitochondrial phospholipids: Role in mitochondrial function","volume":"48","author":"Mejia","year":"2016","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbalip.2011.09.009","article-title":"Phosphatidylcholine biosynthesis and lipoprotein metabolism","volume":"1821","author":"Cole","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1194\/jlr.R700019-JLR200","article-title":"Phosphatidylcholine and choline homeostasis","volume":"49","author":"Li","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Dutta, A., and Sharma-Walia, N. (2019). Curbing Lipids: Impacts ON Cancer and Viral Infection. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030644"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1242\/dmm.011338","article-title":"Hooked on fat: The role of lipid synthesis in cancer metabolism and tumour development","volume":"6","author":"Baenke","year":"2013","journal-title":"Dis. Models Mech."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2174\/0929867325666180904120029","article-title":"Lipids as Biomarkers of Cancer and Bacterial Infections","volume":"26","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbagen.2013.09.020","article-title":"Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: Implication of reconstituted tumor microenvironment and multidrug resistance phenotype","volume":"1840","author":"Kant","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/1535-7163.MCT-09-1061","article-title":"Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma","volume":"9","author":"Uddin","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tem.2017.11.003","article-title":"Interacting Cancer Machineries: Cell Signaling, Lipid Metabolism, and Epigenetics","volume":"29","author":"Grunt","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pharmthera.2017.02.021","article-title":"Fatty acid synthase\u2014Modern tumor cell biology insights into a classical oncology target","volume":"177","author":"Buckley","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gelebart, P., Zak, Z., Anand, M., Belch, A., and Lai, R. (2012). Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033738"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Puerta, J.A., Espinosa, G., and Cervera, R. (2016). Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies. Antibodies, 5.","DOI":"10.3390\/antib5030018"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jcrc.2014.02.005","article-title":"Antiphospholipid antibodies in critically ill patients with cancer: A prospective cohort study","volume":"29","author":"Vassalo","year":"2014","journal-title":"J. Crit. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11739-016-1596-2","article-title":"Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome","volume":"12","author":"Sciascia","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/cei.13229","article-title":"Anti-beta2 -glycoprotein I antibody with DNA binding activity enters living monocytes via cell surface DNA and induces tissue factor expression","volume":"195","author":"Virachith","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.semcancer.2019.07.019","article-title":"Antiphospholipid antibodies and antiphospholipid syndrome in cancer: Uninvited guests in troubled times","volume":"64","author":"Islam","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.blre.2017.07.006","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"31","author":"Chaturvedi","year":"2017","journal-title":"Blood Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11926-014-0485-9","article-title":"The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome","volume":"17","author":"Willis","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kalgudi, S., and Ho, K.M. (2020). Incidence of Antithrombin Deficiency and Anti-Cardiolipin Antibodies After Severe Traumatic Brain Injury: A Prospective Cohort Study. Neurocrit. Care.","DOI":"10.1007\/s12028-020-01026-x"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.autrev.2016.12.010","article-title":"Detection of lupus anticoagulant in the era of direct oral anticoagulants","volume":"16","author":"Hoxha","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/labmed\/lmy024","article-title":"Antinuclear Antibodies: Marker of Diagnosis and Evolution in Autoimmune Diseases","volume":"49","author":"Sur","year":"2018","journal-title":"Lab. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/bloodadvances.2020001557","article-title":"Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors","volume":"4","author":"Tayar","year":"2020","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e224636","DOI":"10.1136\/bcr-2018-224636","article-title":"Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab","volume":"12","author":"Liu","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10067-018-4062-x","article-title":"Anti-neutrophil cytoplasmic antibodies and their clinical significance","volume":"37","author":"Suwanchote","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"152011","DOI":"10.1016\/j.imbio.2020.152011","article-title":"Anti-neutrophil antibodies (anti-MPO-ANCAs) are associated with poor prognosis in breast cancer patients","volume":"225","author":"Scandolara","year":"2020","journal-title":"Immunobiology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.05.002","article-title":"Antinuclear antibodies and cancer: A literature review","volume":"127","author":"Vlagea","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12032-020-01440-3","article-title":"Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients","volume":"37","author":"Morimoto","year":"2020","journal-title":"Med. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/cei.13136","article-title":"Anti-nuclear antibodies in patients with breast cancer","volume":"193","author":"Nisihara","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5114\/reum.2018.77976","article-title":"Antinuclear antibodies in healthy people and non-rheumatic diseases\u2014Diagnostic and clinical implications","volume":"56","author":"Rogacka","year":"2018","journal-title":"Reumatologia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/CM9.0000000000000114","article-title":"Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia","volume":"132","author":"Sun","year":"2019","journal-title":"Chin. Med. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/0973-1482.183559","article-title":"Clinical significance of elevated antinuclear antibodies in patients with diffuse large B-cell lymphoma: A single center study","volume":"14","author":"Lang","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"ref_43","first-page":"191","article-title":"Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value","volume":"19","author":"Gulbas","year":"2014","journal-title":"JBUON"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1034\/j.1600-0609.2002.01526.x","article-title":"Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin\u2019s lymphoma","volume":"68","author":"Genvresse","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.thj.6200377","article-title":"Antiphospholipid antibodies in lymphoma: Prevalence and clinical significance","volume":"5","author":"Pusterla","year":"2004","journal-title":"Hematol. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1076029620928392","DOI":"10.1177\/1076029620928392","article-title":"High Incidence of Antiphospholipid Antibodies in Newly Diagnosed Patients With Lymphoma and a Proposed aPL Predictive Score","volume":"26","author":"Kungwankiattichai","year":"2020","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nri.2017.105","article-title":"Neutrophil extracellular traps in immunity and disease","volume":"18","author":"Papayannopoulos","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2020.02.011","article-title":"Neutrophil traps, anti-myeloperoxidase antibodies and cancer: Are they linked?","volume":"221","author":"Scandolara","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jbspin.2016.01.012","article-title":"Antineutrophilic cytoplasmic antibody-associated vasculitis and malignant hemopathies, a retrospective study of 16 cases","volume":"84","author":"Philipponnet","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/hematology.2019000073","article-title":"Is there a role for immunosuppression in antiphospholipid syndrome?","volume":"2019","author":"Sevim","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/ijc.31817","article-title":"Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers","volume":"144","author":"Sharma","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-0036-1597290","article-title":"Mechanisms of Cellular Activation in the Antiphospholipid Syndrome","volume":"44","author":"Lackner","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1139\/bcb-2018-0393","article-title":"Annexin A2 expression and partners during epithelial cell differentiation","volume":"97","author":"Zibouche","year":"2019","journal-title":"Biochem. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1038\/s41598-017-03470-w","article-title":"Intracellular targeting of annexin A2 inhibits tumor cell adhesion, migration, and in vivo grafting","volume":"7","author":"Staquicini","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_55","first-page":"5","article-title":"Annexin A2 and cancer: A systematic review","volume":"52","author":"Christensen","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.3748\/wjg.v26.i18.2126","article-title":"Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment","volume":"26","author":"Qiu","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1021\/acs.molpharmaceut.8b00691","article-title":"TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings","volume":"15","author":"Lamprecht","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00018-020-03656-y","article-title":"TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling","volume":"78","author":"Ciesielska","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12199-018-0740-1","article-title":"Inflammation and cancer","volume":"23","author":"Murata","year":"2018","journal-title":"Environ. Health Prev. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann. Afr. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10875-008-9188-1","article-title":"Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome","volume":"28","author":"Salle","year":"2008","journal-title":"J. Clin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cei.12762","article-title":"Antibodies to age-beta2 glycoprotein I in patients with anti-phospholipid antibody syndrome","volume":"184","author":"Sorice","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12026-016-8840-8","article-title":"Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome","volume":"65","author":"Weiss","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15859","DOI":"10.1038\/srep15859","article-title":"Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.molimm.2012.08.012","article-title":"Anti-beta(2)GPI\/beta(2)GPI induced TF and TNF-alpha expression in monocytes involving both TLR4\/MyD88 and TLR4\/TRIF signaling pathways","volume":"53","author":"Xie","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2249.2010.04291.x","article-title":"Toll-like receptor (TLR)-4 mediates anti-beta2GPI\/beta2GPI-induced tissue factor expression in THP-1 cells","volume":"163","author":"Zhou","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.thromres.2013.09.039","article-title":"Anti-beta2GPI\/beta2GPI stimulates activation of THP-1 cells through TLR4\/MD-2\/MyD88 and NF-kappaB signaling pathways","volume":"132","author":"Zhou","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Moitinho","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_70","first-page":"82","article-title":"Primary lymphocytic lymphoma of lacrimal gland","volume":"92","author":"Arcas","year":"2017","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2169\/internalmedicine.56.7806","article-title":"Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome Associated with MALT Lymphoma by Autologous Hematopoietic Stem Cell Transplantation","volume":"56","author":"Oka","year":"2017","journal-title":"Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13223-018-0246-9","article-title":"Case report presenting the diagnostic challenges in a patient with recurrent acquired angioedema, antiphospholipid antibodies and undetectable C2 levels","volume":"14","author":"Bonnin","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.21037\/cdt-20-486","article-title":"A case of acute myelogenous leukemia characterized by arterial and venous thrombosis","volume":"10","author":"Liang","year":"2020","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1177\/0961203320937349","article-title":"Probable catastrophic antiphospholipid syndrome secondary to chronic myelomonocytic leukaemia in an adult patient and a mini review","volume":"29","author":"Meng","year":"2020","journal-title":"Lupus"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/0019-509X.180846","article-title":"Massive pulmonary thrombo-embolism in a case of multiple myeloma and concurrent anti-phospholipid syndrome","volume":"53","author":"Valizadeh","year":"2016","journal-title":"Indian J. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/8\/4151\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:50:51Z","timestamp":1760136651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/8\/4151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":75,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijms23084151"],"URL":"https:\/\/doi.org\/10.3390\/ijms23084151","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]}}}